What is Neuronetics, Inc.'s earnings per share (EPS)?

Neuronetics, Inc. (STIM) reported diluted earnings per share of -$0.59 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neuronetics, Inc. (STIM) Financials

STIM

Trailing 12 months to June 30, 2026

Revenue $155.1M +39.6% YoY

Net Income -$30.4M +37.6% YoY

EPS (Diluted) -$0.44 YoY not available

Free Cash Flow -$11.3M +68.2% YoY

Market Cap $168.4M as of Oct 6, 2026

Price / Sales 1.1x on $155.1M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 9.4x on $17.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the STIM SEC filings page.

Neuronetics, Inc. (STIM) reported $155.1M in revenue over the twelve months to Jun 30, 2026, up 39.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI STIM FY2025 2026-10-03

2025 brought a near doubling of revenue, but weaker gross margins and heavier leverage left the business still dependent on external financing.

Scale improved loss and cash conversion without producing profitability: revenue reached $149.2M while operating cash outflow narrowed to $20.4M, yet gross margin fell to 48.5% from 72.3%. The growth therefore appears to have come with a materially less favorable revenue mix or cost structure, not simply more of the prior economics.

Operating leverage was partial rather than complete. The operating loss narrowed to $31.4M from $34.6M even as selling, general and administrative expense rose to $49.7M; lower research spending helped offset that increase, but the company remained loss-making.

The balance sheet is becoming more debt-dependent. Debt-to-equity reached 2.9x as total liabilities rose to $115.3M and equity fell to $22.4M. Reported liquidity equaled 16.5 months of the latest annual operating outflow, while financing provided $35.9M during FY2025.

Financial Health Signals

Financial Health Score 42/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Neuronetics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Neuronetics, Inc. held $28.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $20.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Neuronetics, Inc. scores 41/100 among other emerging companies.

Dilution

Neuronetics, Inc. had 69M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Neuronetics, Inc. scores 19/100 among other emerging companies.

R&D Intensity

Neuronetics, Inc. spent $6.6M on research and development in fiscal year 2025, which was 3.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Neuronetics, Inc. scores 20/100 among other emerging companies.

Revenue Progress

Neuronetics, Inc. reported revenue of $149.2M in fiscal year 2025, against $74.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Neuronetics, Inc. scores 77/100 among other emerging companies.

Burn Trend

Neuronetics, Inc.'s operations used $20.4M of cash in fiscal year 2025, against $31.0M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Neuronetics, Inc. scores 64/100 among other emerging companies.

Balance Sheet

Neuronetics, Inc.'s cash, cash equivalents and investments came to $28.1M at the end of fiscal year 2025, against $115.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Neuronetics, Inc. scores 30/100 among other emerging companies.

Altman Z-Score Distress

-3.08

Neuronetics, Inc. scores -3.08, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($168.4M) relative to total liabilities ($115.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Neuronetics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Neuronetics, Inc. reported a net loss of $39.0M while operations used $20.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Neuronetics, Inc. reported an operating loss of $31.4M against $7.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$41.6M

YoY+9.1%

QoQ+20.6%

5Y CAGR+24.0%

Neuronetics, Inc. generated $41.6M in revenue in Q2 2026. This represents an increase of 9.1% from the same quarter a year earlier. Against the prior quarter it is up 20.6%.

EBITDA

-$1.1M

YoY+85.4%

QoQ+86.7%

Neuronetics, Inc.'s EBITDA was -$1.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 85.4% from the same quarter a year earlier. Against the prior quarter it is up 86.7%.

Net Income

-$3.4M

YoY+66.0%

QoQ+68.1%

Neuronetics, Inc. reported -$3.4M in net income in Q2 2026. This represents an increase of 66.0% from the same quarter a year earlier. Against the prior quarter it is up 68.1%.

EPS (Diluted)

-$0.05

YoY+66.7%

QoQ+68.8%

Neuronetics, Inc. earned -$0.05 per diluted share (EPS) in Q2 2026. This represents an increase of 66.7% from the same quarter a year earlier. Against the prior quarter it is up 68.8%.

Cash & Balance Sheet

Free Cash Flow

-$1.4M

YoY+62.1%

QoQ+85.2%

Neuronetics, Inc. recorded an outflow of $1.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 62.1% from the same quarter a year earlier. Against the prior quarter it is up 85.2%.

Cash & Debt

$19.2M

YoY+75.0%

QoQ+45.3%

5Y CAGR-30.2%

Neuronetics, Inc. held $19.2M in cash against $61.5M in long-term debt as of Q2 2026.

Shares Outstanding

76M

YoY+15.2%

QoQ+9.5%

5Y CAGR+23.7%

Neuronetics, Inc. had 76M shares outstanding in Q2 2026. This represents an increase of 15.2% from the same quarter a year earlier. Against the prior quarter it is up 9.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

51.1%

YoY+4.5pp

QoQ+4.2pp

5Y change-29.6pp

Neuronetics, Inc.'s gross margin was 51.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.

Operating Margin

-3.6%

YoY+17.5pp

QoQ+22.5pp

5Y change+42.6pp

Neuronetics, Inc.'s operating margin was -3.6% in Q2 2026, reflecting core business profitability. This is up 17.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.5 percentage points.

Net Margin

-8.3%

YoY+18.3pp

QoQ+23.0pp

5Y change+44.7pp

Neuronetics, Inc.'s net profit margin was -8.3% in Q2 2026, showing the share of revenue converted to profit. This is up 18.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 23.0 percentage points.

Return on Equity

-19.3%

YoY+18.0pp

QoQ+62.1pp

Neuronetics, Inc.'s ROE was -19.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 18.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 62.1 percentage points.

Capital Allocation

R&D Spending

$1.3M

YoY-25.7%

QoQ-2.1%

5Y CAGR-10.2%

Neuronetics, Inc. invested $1.3M in research and development in Q2 2026. This represents a decrease of 25.7% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.

Capital Expenditures

$417K

YoY+65.5%

QoQ+111.7%

5Y CAGR-0.8%

Neuronetics, Inc. invested $417K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 65.5% from the same quarter a year earlier. Against the prior quarter it is up 111.7%.

Share Buybacks

Not reported for Q2 2026.

STIM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

STIM quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	$155.1M	$149.2M+99.2%	$74.9M+5.0%	$71.3M+9.4%	$65.2M+17.9%	$55.3M+12.3%	$49.2M-21.4%	$62.7M+18.7%	$52.8M+30.5%	$40.4M+18.1%	$34.2M
Cost of Revenue	$78.9M	$76.8M+270.7%	$20.7M+5.5%	$19.6M+26.9%	$15.5M+32.9%	$11.7M+0.9%	$11.6M-24.9%	$15.4M+23.6%	$12.4M+29.2%	$9.6M+45.5%	$6.6M
Gross Profit	$76.2M	$72.3M+33.5%	$54.2M+4.8%	$51.7M+4.0%	$49.7M+13.9%	$43.7M+15.8%	$37.7M-20.3%	$47.3M+17.2%	$40.3M+30.9%	$30.8M+11.6%	$27.6M
R&D Expenses	$5.9M	$6.6M-48.4%	$12.8M+34.2%	$9.5M+1.9%	$9.3M+17.8%	$7.9M-13.9%	$9.2M-33.1%	$13.7M+67.0%	$8.2M+3.7%	$7.9M-3.5%	$8.2M
SG&A Expenses	$48.9M	$49.7M+63.9%	$30.3M+19.3%	$25.4M-0.4%	$25.5M-0.1%	$25.6M+40.1%	$18.2M+4.5%	$17.5M+27.7%	$13.7M+59.4%	$8.6M+23.8%	$6.9M
Operating Income	-$22.9M	-$31.4M+9.0%	-$34.6M-13.1%	-$30.6M+13.0%	-$35.1M-27.4%	-$27.6M-23.6%	-$22.3M+17.2%	-$26.9M-35.8%	-$19.8M-45.8%	-$13.6M-45.7%	-$9.3M
EBITDA	N/A	-$28.0M+13.9%	-$32.5M-13.8%	-$28.5M+14.7%	-$33.5M-26.3%	-$26.5M-24.0%	-$21.4M+17.4%	-$25.9M-36.5%	-$19.0M-45.7%	-$13.0M-50.2%	-$8.7M
Interest Expense	$8.1M	$7.6M+4.3%	$7.3M+34.3%	$5.4M+27.6%	$4.3M+5.8%	$4.0M-11.1%	$4.5M+22.7%	$3.7M-0.1%	$3.7M+31.3%	$2.8M+53.0%	$1.8M
Net Income	-$30.4M	-$39.0M+10.8%	-$43.7M-44.8%	-$30.2M+18.8%	-$37.2M-19.1%	-$31.2M-13.6%	-$27.5M+5.5%	-$29.0M-20.5%	-$24.1M-50.1%	-$16.1M-42.9%	-$11.2M
EPS (Basic)	N/A	-$0.59+57.2%	-$1.38-31.4%	-$1.05+23.9%	-$1.38-13.1%	-$1.22+16.4%	-$1.46+7.6%	-$1.58	N/A	N/A	N/A
EPS (Diluted)	-$0.44	-$0.59	-$1.38	-$1.05+23.9%	-$1.38-13.1%	-$1.22+16.4%	-$1.46+7.6%	-$1.58	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	66M	32M	29M+6.5%	27M+5.6%	25M+35.3%	19M+2.5%	18M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$41.6M+9.1%	$34.5M+7.8%	$41.8M+85.7%	$37.3M+101.3%	$38.1M+131.7%	$32.0M+83.6%	$22.5M+8.0%	$18.5M+6.7%
Cost of Revenue	$20.3M0.0%	$18.3M+12.7%	$20.1M+164.1%	$20.2M+345.8%	$20.4M+376.5%	$16.2M+275.1%	$7.6M+67.3%	$4.5M-26.0%
Gross Profit	$21.2M+19.5%	$16.2M+2.6%	$21.7M+45.7%	$17.1M+22.2%	$17.8M+45.8%	$15.7M+20.2%	$14.9M-48.0%	$14.0M+24.5%
R&D Expenses	$1.3M-25.7%	$1.4M-15.6%	$1.7M-71.1%	$1.5M-37.7%	$1.8M-19.6%	$1.6M-31.2%	$5.8M+36.6%	$2.4M+1653.6%
SG&A Expenses	$11.4M-6.1%	$13.0M-0.7%	$13.3M+11.8%	$11.1M+76.1%	$12.2M+97.6%	$13.1M+120.5%	$11.9M+79.9%	$6.3M+5.1%
Operating Income	-$1.5M+81.4%	-$9.0M+18.3%	-$5.0M+56.0%	-$7.3M+5.3%	-$8.1M+5.3%	-$11.0M-60.6%	-$11.5M-159.1%	-$7.7M+12.9%
EBITDA	-$1.1M+85.4%	-$8.3M+18.3%	-$3.5M+68.4%	-$6.8M+5.6%	-$7.6M+4.4%	-$10.1M-60.4%	-$11.1M-180.8%	-$7.2M+13.7%
Interest Expense	$2.1M+7.9%	$2.3M+17.9%	$1.5M-14.5%	$2.2M+27.9%	$2.0M-0.5%	$1.9M+5.3%	$1.8M+2962.4%	$1.7M-44.1%
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$3.4M+66.0%	-$10.8M+14.9%	-$7.2M+43.5%	-$9.0M+32.2%	-$10.1M-2.9%	-$12.7M-61.0%	-$12.7M-891.8%	-$13.3M+1.1%
EPS (Basic)	-$0.05+66.7%	-$0.16+23.8%	-$0.10+78.3%	-$0.13+70.5%	-$0.15+54.5%	-$0.21+22.2%	-$0.46-475.0%	-$0.44-37.5%
EPS (Diluted)	-$0.05+66.7%	-$0.16+23.8%	-$0.10	-$0.13	-$0.15	-$0.21	-$0.46	-$0.44-37.5%
Diluted Shares (Avg)	73M+10.5%	70M+13.2%	N/A	67M	66M	61M	N/A	30M-28.3%

STIM Balance Sheet

STIM quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$141.6M+0.5%	$140.9M+21.6%	$115.8M-0.9%	$116.9M-17.2%	$141.2M+79.5%	$78.7M-21.5%	$100.2M-14.4%	$117.0M+200.5%	$38.9M	N/A
Current Assets	$61.6M+5.9%	$58.1M-38.0%	$93.8M-5.0%	$98.8M-14.4%	$115.3M+77.4%	$65.0M-26.5%	$88.5M-22.7%	$114.5M+209.3%	$37.0M	N/A
Cash & Equivalents	$28.1M+52.4%	$18.5M-69.1%	$59.7M-15.2%	$70.3M-25.3%	$94.1M+92.3%	$49.0M-35.3%	$75.7M-27.6%	$104.6M+258.8%	$29.1M+71.1%	$17.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$4.3M+1.9%	$4.2M-47.5%	$8.1M-9.1%	$8.9M+35.6%	$6.6M+76.4%	$3.7M+34.1%	$2.8M+14.1%	$2.4M-1.5%	$2.5M	N/A
Accounts Receivable	$16.5M-29.5%	$23.4M+48.0%	$15.8M+16.1%	$13.6M+76.4%	$7.7M+7.5%	$7.2M+9.1%	$6.6M+16.9%	$5.6M+31.7%	$4.3M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$23.6M+26.8%	$18.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$115.3M+5.7%	$109.1M+33.6%	$81.6M+36.5%	$59.8M+6.7%	$56.0M+5.4%	$53.2M+1.6%	$52.3M+13.8%	$46.0M-80.1%	$231.6M	N/A
Current Liabilities	$30.5M-2.4%	$31.3M+57.8%	$19.8M-40.3%	$33.2M+111.4%	$15.7M+14.8%	$13.7M-50.6%	$27.7M+104.2%	$13.6M+13.0%	$12.0M	N/A
Non-Current Liabilities	$84.8M+8.9%	$77.8M+25.9%	$61.8M+132.2%	$26.6M-34.0%	$40.3M+2.2%	$39.5M+60.3%	$24.6M-24.1%	$32.4M-85.2%	$219.6M	N/A
Long-Term Debt	$65.8M+19.3%	$55.2M-7.0%	$59.3M+159.7%	$22.8M-35.4%	$35.3M+2.1%	$34.6M+74.0%	$19.9M-34.5%	$30.4M+2.8%	$29.6M	N/A
Total Equity	$22.4M-19.2%	$27.7M-19.0%	$34.2M-40.1%	$57.1M-33.0%	$85.2M+234.1%	$25.5M-46.7%	$47.9M-32.6%	$71.0M+136.9%	-$192.7M-8.8%	-$177.1M
Retained Earnings	-$458.8M-9.3%	-$419.8M-11.6%	-$376.1M-8.7%	-$345.9M-12.0%	-$308.7M-11.2%	-$277.5M-11.0%	-$250.1M-13.1%	-$221.0M-12.2%	-$196.9M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$131.5M-2.3%	$125.4M-11.7%	$141.6M+0.5%	$145.5M+191.6%	$134.7M+39.1%	$142.0M+36.8%	$140.9M+21.6%	$49.9M-46.4%
Current Assets	$53.2M-5.2%	$47.2M-22.2%	$61.6M+5.9%	$64.9M+230.3%	$56.1M-25.6%	$60.7M-25.9%	$58.1M-38.0%	$19.6M-72.3%
Cash & Equivalents	$19.2M+75.0%	$13.2M-34.7%	$28.1M+52.4%	$28.0M+34.0%	$11.0M-74.3%	$20.2M-57.6%	$18.5M-69.1%	$20.9M-41.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$5.5M+11.3%	$4.7M+15.9%	$4.3M+1.9%	$4.3M-12.9%	$4.9M-19.5%	$4.1M-39.2%	$4.2M-47.5%	$5.0M-49.1%
Accounts Receivable	$16.0M-38.9%	$15.8M-39.7%	$16.5M-29.5%	$18.7M+48.0%	$26.1M+52.3%	$26.2M+49.7%	$23.4M+48.0%	$12.6M-15.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$23.6M+23.8%	$23.6M+26.8%	$23.6M+26.8%	$22.7M	$19.1M	$18.6M	$18.6M	N/A
Total Liabilities	$109.9M+6.5%	$108.4M+5.8%	$115.3M+5.7%	$114.1M-40.1%	$103.1M+33.2%	$102.5M+34.5%	$109.1M+33.6%	$190.4M+245.9%
Current Liabilities	$28.3M+1.8%	$28.3M+13.9%	$30.5M-2.4%	$28.9M-22.8%	$27.8M-5.0%	$24.8M+71.3%	$31.3M+57.8%	$37.5M+144.3%
Non-Current Liabilities	$81.6M+8.3%	$80.1M+3.2%	$84.8M+8.9%	$85.2M-44.3%	$75.3M+56.4%	$77.6M+25.9%	$77.8M+25.9%	$152.9M+285.1%
Long-Term Debt	$61.5M+10.8%	$61.3M+10.8%	$65.8M+19.3%	$65.7M+42.8%	$55.5M+20.4%	$55.3M-6.9%	$55.2M-7.0%	$46.0M+24.8%
Total Equity	$17.9M-34.2%	$13.3M-62.6%	$22.4M-19.2%	$27.4M+120.0%	$27.1M+40.0%	$35.5M+28.2%	$27.7M-19.0%	-$136.9M-460.9%
Retained Earnings	-$473.2M-6.9%	-$469.6M-8.6%	-$458.8M-9.3%	-$451.6M-71.3%	-$442.6M-12.4%	-$432.5M-12.6%	-$419.8M-11.6%	-$263.7M+28.9%

STIM Cash Flow Statement

STIM quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$10.3M	-$20.4M+34.2%	-$31.0M+3.2%	-$32.0M-4.2%	-$30.7M-9.8%	-$28.0M+1.4%	-$28.4M+6.9%	-$30.5M-48.0%	-$20.6M-84.8%	-$11.1M-30.5%	-$8.5M
Depreciation & Amortization	N/A	$3.5M+67.1%	$2.1M+3.3%	$2.0M+21.7%	$1.6M+55.5%	$1.1M+12.6%	$941K-11.6%	$1.1M+20.7%	$882K+48.0%	$596K-11.4%	$673K
Stock-Based Compensation	N/A	$6.8M+22.2%	$5.6M-23.5%	$7.3M-16.3%	$8.7M+11.1%	$7.9M+78.7%	$4.4M+28.2%	$3.4M+97.0%	$1.7M+251.4%	$496K+208.1%	$161K
Capital Expenditures	$944K	$801K-45.4%	$1.5M-38.1%	$2.4M-27.5%	$3.3M+38.9%	$2.4M+222.3%	$730K-10.2%	$813K-19.6%	$1.0M+70.2%	$594K+83.3%	$324K
Free Cash Flow	-$11.3M	-$21.2M+34.7%	-$32.5M+5.7%	-$34.4M-1.2%	-$34.0M-12.1%	-$30.3M-4.2%	-$29.1M+6.9%	-$31.3M-44.9%	-$21.6M-84.0%	-$11.7M-32.4%	-$8.9M
Investing Cash Flow	-$919K	-$801K+66.8%	-$2.4M-82.5%	-$1.3M-119.6%	$6.7M+168.4%	-$9.8M-1247.8%	-$730K+10.2%	-$813K+19.6%	-$1.0M-70.2%	-$594K-83.3%	-$324K
Financing Cash Flow	$18.7M	$35.9M+626.6%	-$6.8M-130.0%	$22.7M+10864.7%	$207K-99.8%	$83.0M+3403.8%	$2.4M-2.1%	$2.4M-97.5%	$97.0M+307.0%	$23.8M+387.0%	$4.9M
Dividends Paid	N/A	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.0M+71.2%	-$9.4M+44.6%	$882K+110.3%	-$785K+85.5%	-$3.5M+29.5%	-$17.0M-41.4%	-$8.6M+27.2%	-$5.4M-241.7%
Depreciation & Amortization	$400K-20.0%	$745K-18.2%	$767K+72.0%	$500K0.0%	$500K-16.7%	$911K+62.7%	$446K-9.0%	$500K0.0%
Stock-Based Compensation	$688K-62.1%	$1.7M+16.1%	N/A	$1.4M-0.7%	$1.8M+16.1%	$1.4M+7.9%	N/A	$1.4M+9526.9%
Capital Expenditures	$417K+65.5%	$197K-10.0%	$216K+142.7%	$114K-70.5%	$252K-59.1%	$219K-41.6%	$89K-96.2%	$386K-56.9%
Free Cash Flow	-$1.4M+62.1%	-$9.6M+44.1%	$666K+107.7%	-$899K+84.5%	-$3.8M+32.7%	-$17.2M-38.9%	-$8.7M+38.6%	-$5.8M-298.2%
Investing Cash Flow	-$417K-65.5%	-$172K+21.5%	-$216K+90.9%	-$114K-914.3%	-$252K-111.8%	-$219K-422.1%	-$2.4M-85.9%	$14K-98.2%
Financing Cash Flow	$7.4M+740700.0%	-$5.6M-129.4%	-$1.0M-110.8%	$17.9M	$1K	$19.0M	$9.6M+195.2%	N/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

STIM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

STIM quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Gross Margin	48.5%-23.8pp	72.3%-0.2pp	72.5%-3.8pp	76.3%-2.7pp	78.9%+2.4pp	76.5%+1.1pp	75.4%-1.0pp	76.4%+0.2pp	76.2%-4.5pp	80.7%
Operating Margin	-21.1%+25.1pp	-46.2%-3.3pp	-42.8%+11.0pp	-53.8%-4.0pp	-49.8%-4.5pp	-45.3%-2.3pp	-43.0%-5.4pp	-37.6%-3.9pp	-33.7%-6.4pp	-27.3%
Net Margin	-26.2%+32.2pp	-58.4%-16.1pp	-42.3%+14.7pp	-57.0%-0.6pp	-56.4%-0.6pp	-55.8%-9.4pp	-46.4%-0.7pp	-45.7%-5.9pp	-39.7%-6.9pp	-32.8%
Return on Equity	-174.3%-16.5pp	-157.8%-69.5pp	-88.3%-23.2pp	-65.1%-28.5pp	-36.6%+71.1pp	-107.7%-47.0pp	-60.7%-26.8pp	-33.9%	N/A	N/A
Return on Assets	-27.6%+3.5pp	-31.0%-5.0pp	-26.1%+5.7pp	-31.8%-9.7pp	-22.1%+12.8pp	-34.9%-5.9pp	-29.0%-8.4pp	-20.6%+20.6pp	-41.2%	N/A
Current Ratio	2.02+0.2x	1.86-2.9x	4.73+1.8x	2.98-4.4x	7.34+2.6x	4.75+1.6x	3.19-5.2x	8.44+5.4x	3.09	N/A
Debt-to-Equity	2.94+1.0x	1.99+0.3x	1.73+1.3x	0.400.0x	0.41-0.9x	1.36+0.9x	0.420.0x	0.43	N/A	N/A
Asset Turnover	1.05+0.5x	0.53-0.1x	0.62+0.1x	0.56+0.2x	0.39-0.2x	0.630.0x	0.63+0.2x	0.45-0.6x	1.04	N/A
FCF Margin	-14.2%+29.1pp	-43.4%+4.9pp	-48.2%+3.9pp	-52.1%+2.7pp	-54.9%+4.3pp	-59.1%-9.2pp	-50.0%-9.0pp	-40.9%-11.9pp	-29.0%-3.1pp	-25.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	51.1%+4.5pp	46.9%-2.3pp	51.9%-14.3pp	45.9%-29.7pp	46.6%-27.4pp	49.2%-25.9pp	66.2%	75.6%+10.8pp
Operating Margin	-3.6%+17.5pp	-26.1%+8.3pp	-12.1%+38.9pp	-19.6%+22.1pp	-21.1%+30.6pp	-34.4%+4.9pp	-51.0%-29.7pp	-41.7%+9.4pp
Net Margin	-8.3%+18.3pp	-31.3%+8.3pp	-17.1%+39.2pp	-24.3%+47.8pp	-26.6%+33.2pp	-39.6%+5.6pp	-56.3%-50.2pp	-72.0%+5.7pp
Return on Equity	-19.3%+18.0pp	-81.3%-45.6pp	-32.0%+13.7pp	-33.1%	-37.3%+13.4pp	-35.8%-7.3pp	-45.7%-42.0pp	N/A
Return on Assets	-2.6%+4.9pp	-8.6%+0.3pp	-5.1%+3.9pp	-6.2%+20.5pp	-7.5%+2.6pp	-8.9%-1.3pp	-9.0%-7.9pp	-26.8%-12.2pp
Current Ratio	1.88-0.1x	1.67-0.8x	2.02+0.2x	2.24+1.7x	2.02-0.6x	2.44-3.2x	1.86-2.9x	0.52-4.1x
Debt-to-Equity	3.45+1.4x	4.62+3.1x	2.94+1.0x	2.40	2.05-0.3x	1.56-0.6x	1.99+0.3x	N/A
Asset Turnover	0.320.0x	0.270.0x	0.30+0.1x	0.26-0.1x	0.28+0.1x	0.23+0.1x	0.160.0x	0.37+0.2x
FCF Margin	-3.4%+6.4pp	-27.9%+25.9pp	1.6%+40.2pp	-2.4%+28.9pp	-9.9%+24.1pp	-53.8%+17.3pp	-38.6%+29.3pp	-31.3%-48.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Neuronetics, Inc. STIM	FY2025	$149.2M	-$39.0M	-26.2%	$168.4M	42/100
TriSalus Life Sciences, Inc. TLSI	FY2025	$45.2M	-$39.2M	-86.9%	$269.7M	50/100
CVRx, Inc. CVRX	FY2025	$56.7M	-$53.3M	-94.1%	$41.6M	50/100
BioSig Technologies, Inc. BSGM	FY2025	N/A	-$462.8M	N/A	$157.0M	—
Electromed, Inc. ELMD	FY2026	$73.8M	$11.3M	15.3%	$234.7M	79/100
Brainsway Ltd. BWAY	FY2024	$41.0M	$2.9M	7.1%	$492.3M	36/100

Where Neuronetics, Inc. Ranks

Frequently Asked Questions

What is Neuronetics, Inc.'s annual revenue?

Neuronetics, Inc. (STIM) reported $149.2M in total revenue for fiscal year 2025. This represents a 99.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Neuronetics, Inc.'s revenue growing?

Neuronetics, Inc. (STIM) revenue grew by 99.2% year-over-year, from $74.9M to $149.2M in fiscal year 2025.

Is Neuronetics, Inc. profitable?

No, Neuronetics, Inc. (STIM) reported a net income of -$39.0M in fiscal year 2025, with a net profit margin of -26.2%.

What is Neuronetics, Inc.'s EBITDA?

Neuronetics, Inc. (STIM) had EBITDA of -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Neuronetics, Inc. have?

As of fiscal year 2025, Neuronetics, Inc. (STIM) had $28.1M in cash and equivalents against $65.8M in long-term debt.

What is Neuronetics, Inc.'s gross margin?

Neuronetics, Inc. (STIM) had a gross margin of 48.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Neuronetics, Inc.'s operating margin?

Neuronetics, Inc. (STIM) had an operating margin of -21.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Neuronetics, Inc.'s net profit margin?

Neuronetics, Inc. (STIM) had a net profit margin of -26.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Neuronetics, Inc.'s return on equity (ROE)?

Neuronetics, Inc. (STIM) has a return on equity of -174.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Neuronetics, Inc.'s free cash flow?

Neuronetics, Inc. (STIM) recorded an outflow of $21.2M in free cash flow during fiscal year 2025. This represents a 34.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Neuronetics, Inc.'s operating cash flow?

Neuronetics, Inc. (STIM) recorded an outflow of $20.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Neuronetics, Inc.'s total assets?

Neuronetics, Inc. (STIM) had $141.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Neuronetics, Inc.'s capital expenditures?

Neuronetics, Inc. (STIM) invested $801K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Neuronetics, Inc. spend on research and development?

Neuronetics, Inc. (STIM) invested $6.6M in research and development during fiscal year 2025.

How many shares does Neuronetics, Inc. have outstanding?

Neuronetics, Inc. (STIM) had 69M shares outstanding as of fiscal year 2025.

What is Neuronetics, Inc.'s current ratio?

Neuronetics, Inc. (STIM) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.

What is Neuronetics, Inc.'s debt-to-equity ratio?

Neuronetics, Inc. (STIM) had a debt-to-equity ratio of 2.94 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Neuronetics, Inc.'s return on assets (ROA)?

Neuronetics, Inc. (STIM) had a return on assets of -27.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Neuronetics, Inc.'s P/E ratio?

Neuronetics, Inc. (STIM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $168.4M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Neuronetics, Inc.'s price-to-sales ratio?

Neuronetics, Inc. (STIM) trades at 1.1x sales, its market capitalization divided by revenue of $155.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $168.4M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Neuronetics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Neuronetics, Inc. (STIM) held $28.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $20.4M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Neuronetics, Inc.'s Altman Z-Score?

Neuronetics, Inc. (STIM) has an Altman Z-Score of -3.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Neuronetics, Inc.'s Piotroski F-Score?

Neuronetics, Inc. (STIM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Neuronetics, Inc.'s earnings high quality?

Neuronetics, Inc. (STIM) reported a net loss of $39.0M while operations used $20.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Neuronetics, Inc. cover its interest payments?

Neuronetics, Inc. (STIM) reported an operating loss of $31.4M against $7.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Neuronetics, Inc.?

Neuronetics, Inc. (STIM) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.